Can These 3 Healthcare Dividend Stocks Deliver Income Growth?

Mon., September 18, 2023 | Kate Stalter

Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should you invest $1,000 in Gilead Sciences right now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Gilead Sciences (GILD)	3.5744 of 5 stars	$75.18	-0.5%	3.99%	17.28	Moderate Buy	$90.05
Medtronic (MDT)	2.9543 of 5 stars	$77.47	-1.9%	3.56%	28.59	Hold	$91.67
Pfizer (PFE)	3.2751 of 5 stars	$31.91	-1.5%	5.14%	8.49	Hold	$46.35
Eli Lilly and Company (LLY)	2.7522 of 5 stars	$544.66	-1.0%	0.83%	75.75	Moderate Buy	$532.78

Compare These Stocks Add These Stocks to My Watchlist

About Kate Stalter

Contributing Author: Retirement, Asset Allocation, and Tax Strategies

Kate Stalter is a Series 65-licensed asset manager, with more than two decades of experience in various areas of financial services. As an investment advisor and financial planner, Kate personally manages client portfolios, with a focus on successful retirement, including asset allocation, income generation and tax strategies. Kate also serves as a capital-markets contributor at Forbes.com, and is an expert columnist for the investment advisory channel at U.S. News & World Report.

Contact Kate Stalter via email at stalterkate@gmail.com.